secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2024-12-27T23:59:59+00:00
Accession:  0000950170-24-140833
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences CMO departing Dec 31; Kirk Ways named interim CMO
--------------------------------------------------------------------

- Dr. Ralph Charlton III's employment ends Dec 31, 2024; severance includes $343,200 lump sum plus 9 months COBRA.
- Dr. Kirk Ways (73), Board member since June 2021, appointed interim CMO effective Dec 20, 2024.
- Ways previously served as interim CMO of MBX Biosciences and Development Head at Janssen.
- Severance amount equals 9 months of base salary at $343,200 paid as lump sum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000095017024140833/0000950170-24-140833-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000095017024140833/sprb-20241220.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-140833

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer